182 related articles for article (PubMed ID: 26987991)
1. Analysis of HER2 status in gastroesophageal tumor specimens using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
Viale G; Paterson J; Bloch M; Csathy G; Allen D; Dell'Orto P; Kjærsgaard G; Levy YY; Jørgensen JT
Histol Histopathol; 2016 Dec; 31(12):1327-35. PubMed ID: 26987991
[TBL] [Abstract][Full Text] [Related]
2. Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
Viale G; Paterson J; Bloch M; Csathy G; Allen D; Dell'Orto P; Kjærsgaard G; Levy YY; Jørgensen JT
Pathol Res Pract; 2016 Aug; 212(8):735-42. PubMed ID: 27461826
[TBL] [Abstract][Full Text] [Related]
3. Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.
Franchet C; Filleron T; Cayre A; Mounié E; Penault-Llorca F; Jacquemier J; Macgrogan G; Arnould L; Lacroix-Triki M
Histopathology; 2014 Jan; 64(2):274-83. PubMed ID: 24117939
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
[TBL] [Abstract][Full Text] [Related]
5. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
6. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
Grin A; Brezden-Masley C; Bauer S; Streutker CJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies.
Hicks D; Dell'Orto P; Falzon M; Hoff KD; Levy YY; McMahon L; Miller K; Russo L; Viale G
Appl Immunohistochem Mol Morphol; 2017; 25(5):313-319. PubMed ID: 26657878
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
9. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
10. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
[TBL] [Abstract][Full Text] [Related]
11. Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH.
Yoon N; Do IG; Cho EY
APMIS; 2014 Sep; 122(9):755-60. PubMed ID: 24372629
[TBL] [Abstract][Full Text] [Related]
12. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
[TBL] [Abstract][Full Text] [Related]
13. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
14. Potential impact of HercepTest™ mAb PharmDx (Dako Omnis) (ge001) in breast cancer diagnosis.
Marszałek A; Kubicka A; Jagiełło I; Malicka-Durczak A
Pol J Pathol; 2023; 74(2):82-88. PubMed ID: 37728467
[TBL] [Abstract][Full Text] [Related]
15. [A FISH analysis in one day. Experience in evaluating HER2 gene status by means of a new HER2 IQFISH pharmdx kit].
Zavalishina LÉ; Petrov AV; Pavlenko IA; Gorelik MZ
Arkh Patol; 2013; 75(1):52-3. PubMed ID: 23805475
[TBL] [Abstract][Full Text] [Related]
16. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
[TBL] [Abstract][Full Text] [Related]
17. HER2 testing in gastric cancer: An update.
Abrahao-Machado LF; Scapulatempo-Neto C
World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
Han X; Shi Y; Ma L; Lyu Z; Yang H; Yao J; Li J; Li B; Qin Y
Chin Med J (Engl); 2014; 127(2):246-53. PubMed ID: 24438611
[TBL] [Abstract][Full Text] [Related]
19. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases.
Staněk L; Rozkoš T; Laco J; Ryška A; Petruželka L; Důra M; Dundr P
Mol Med Rep; 2014 Nov; 10(5):2669-74. PubMed ID: 25189406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
